Compare enteric and sustained-release pharma pellets, review acid-stage and multi-point dissolution data, and plan a MUPS tablet compression trial.
R
Rraynex Editorial Team
3 min read
Overview
Enteric-coated and sustained-release pellets both modify when an active ingredient is released. Enteric coating is used to delay release under acidic conditions. Sustained-release design extends release over time. In a multiple-unit pellet system (MUPS) tablet, compression adds another variable because it can damage the pellet coating and change the finished tablet’s release profile.
For a supplier comparison, start with the intended dosage form and the test data you need to qualify it. Ask both suppliers to identify the material, test method, reporting basis and sample batch so your formulation and quality teams can compare like with like.
Compare the release objectives
Release and process evidence to request
Design
Evaluation question
Evidence to request
Enteric-coated (EC)
Does the material resist release in the acid stage and release as intended after the medium changes?
Acid-stage and subsequent release results, with medium, duration, method and acceptance criteria for both stages.
Sustained release (SR)
Does release follow the intended profile across the specified time points?
A dissolution profile with sampling times, units, apparatus, medium and agitation conditions.
MUPS tablet
Does the intended tablet process preserve the required performance of the coated units?
Pellet and finished-tablet data, trial settings and the basis for comparing release before and after compaction.
Enteric coating and the acid-stage result
Ask for both stages of the proposed test. An acid-stage result addresses gastro-resistance under the stated test conditions. The next stage addresses how the product releases after the transition. Ask how the laboratory changes the medium and when the time for the second stage starts. A result expressed as a percentage is meaningful only when the method, basis and time point are clear.
When reviewing an Esomeprazole EC Pellets or Rabeprazole EC Pellets enquiry, identify the exact active form and loading basis. If the project requires a dual delayed-release design, use the Dexlansoprazole DDR reference and ask how each release stage is assessed. These entries identify catalogue materials for enquiry.
Sustained release and the shape of the profile
An endpoint can hide differences earlier in the test. Request results at the proposed early, intermediate and later sampling times and ask how variability between units is reported. Record method differences before comparing offers. If one profile uses a different apparatus, agitation rate or medium, ask your laboratory how to make a valid comparison.
For Tamsulosin HCl SR Pellets or Mebeverine HCl SR Pellets, include the target loading, downstream process and the time points of interest in the enquiry. Agree the tests with the team responsible for the finished dosage form.
Evaluate compression for a MUPS tablet
Plan the comparison around the coated pellets as supplied and tablets from the intended trial process. Record the pellet fraction, excipients, tooling and compression settings. Evaluate blend handling and unit uniformity alongside release. If the release profile changes, check how the tablet disintegrates and whether the coating has been affected before changing the trial conditions.
A published compaction study on sustained-release model pellets found that core material, coat properties, compaction pressure and pellet arrangement can influence release after tableting. Use those variables to frame the trial for your own formulation. Journal of Pharmacy and Pharmacology compaction study
Prepare the comparison before requesting samples
Define the intended finished dosage form, exact catalogue reference and release objective.
Ask what specification and batch-linked dissolution data can be reviewed before trial.
Record the method, reporting basis and test conditions for each proposed material.
Define the downstream trial and who will review discrepancies, especially after compression.
The EMA guideline provides background on dissolution and gastro-resistance for finished oral modified-release products. Agree pellet acceptance criteria for the exact material and project. EMA guideline on quality of oral modified-release products
Frequently Asked Questions
Can two sustained-release pellet samples be compared using one dissolution time point?
Use the time points relevant to the target profile. A single time point can miss early release differences and changes later in the test.
What does MUPS tell me about the release profile?
MUPS describes a multiple-unit pellet system. Confirm the release objective separately and evaluate it in the intended dosage form.
What should I include in a Rraynex MUPS enquiry?
Identify the Omeprazole MUPS or Esomeprazole MUPS reference, the intended tablet process and the release data your formulation team needs.
Put insight into practice
Let’s discuss your next formulation project.
Share your product, strength, release requirements, expected quantity and destination market with our team.
A guide to pharmaceutical pellets for formulators. Learn about pelletisation, release designations and what to confirm when evaluating a pellet specification.
Discover why APIs are the backbone of every drug formulation. Learn about the critical role of API quality, physical attributes, and how they impact therapeutic success.
Explore pharmaceutical pellet and DC granule manufacturing, pilot-to-commercial scale-up, process validation, formulation development and bulk supply planning in India.